article thumbnail

STAT+: FDA is still struggling with a lack of inspectors, but doesn’t have a plan, watchdog finds

STAT

In the wake of the Covid-19 pandemic, the Food and Drug Administration continues to struggle with a lack of investigators needed to inspect domestic and foreign pharmaceutical manufacturing plants and has not yet developed a plan to keep needed staff, a U.S. government watchdog found.

article thumbnail

STAT+: FDA efforts to oversee foreign drug manufacturing remain inadequate to ensure safety, analysis finds

STAT

Specifically, there was a 79% drop in inspections of pharmaceutical manufacturing plants in foreign countries and a 35% decline in domestic facilities from 2019 to 2022. Meanwhile, FDA budgeting and staffing held steady, although resources allocated for each inspection surged and more plants were cited for serious violations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sustainable energy strategies for pharmaceutical manufacturers

European Pharmaceutical Review

The pharmaceutical sector is not typically seen as a highly polluting, ‘heavy industry’ but it is far from green. In its 2021 report Delivering a ‘Net Zero’ National Health Service , the UK’s NHS attributes as much as a quarter of its carbon footprint to medicines. About the author.

article thumbnail

Pharmaceutical Manufacturing and Packaging Congress 2021

pharmaphorum

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2021) will be held on the 28th – 29th of June, 2021 at the BGS online platform. Pharmaceutical Manufacturing & Packaging Congress provides the networking platform for the decision-makers from the pharmaceutical industry.

article thumbnail

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers

Drug Channels

Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021. You can find links to each company’s data below. healthcare expenditures.

article thumbnail

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers (rerun)

Drug Channels

Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021. You can find links to each company’s data below. healthcare expenditures.

article thumbnail

Asahi Kasei establishes life science division to streamline bioprocess operations for pharma sector

Express Pharma

based Bionique Testing Laboratories (2021), and biologics CDMO Bionova Scientific (2022). These technologies are part of the larger effort to support pharmaceutical manufacturers with enhanced process efficiency and product safety.